R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.
Lamy, Thierry; Damaj, Gandhi; Soubeyran, Pierre; Gyan, Emmanuel; Cartron, Guillaume; Bouabdallah, Krimo; Gressin, Rémy; Cornillon, Jérôme; Banos, Anne; Le Du, Katell; Benchalal, Mohamed; Moles, Marie-Pierre; Le Gouill, Steven; Fleury, Joel; Godmer, Pascal; Maisonneuve, Hervé; Deconinck, Eric; Houot, Roch; Laribi, Kamel; Marolleau, Jean Pierre; Tournilhac, Olivier; Branger, Bernard; Devillers, Anne; Vuillez, Jean Philippe; Fest, Thierry; Colombat, Philippe; Costes, Valérie; Szablewski, Vanessa; Béné, Marie C; Delwail, Vincent.
; 131(2): 174-181, 2018 01 11.
Artigo em Inglês | MEDLINE | ID: mdl-29061568
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Treatment of older patients with mantle-cell lymphoma.